We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
One of the Democrats’ campaign promises took another step forward late Thursday night as the Senate Finance Committee approved a bill that would allow the HHS secretary to negotiate prices with companies for Medicare Part D prescription drugs.
The Senate passed a measure easing restrictions on federal funding for embryonic stem cell research that President Bush has vowed to veto if it reaches his desk.
Sen. Edward Kennedy (D-Mass.) introduced the Prescription Drug User Fee Act (PDUFA) reauthorization last week, proposing a new structure that would increase the agency’s user fees by more than $100 million.
One of the Democrats' campaign promises took another step forward last week as the Senate Finance Committee approved a bill that would allow the HHS secretary to negotiate prices with companies for Medicare Part D prescription drugs.
The Senate passed a measure easing restrictions on federal funding for embryonic stem cell research that President Bush has vowed to veto if it reaches his desk.
Sen. Edward Kennedy (D-Mass.) introduced the Prescription Drug User Fee Act (PDUFA) reauthorization this week, proposing a new structure that would increase the agency’s user fees by more than $100 million.
PhRMA voiced opposition to proposed legislation that would create a pathway for the FDA to approve follow-on biologics because it will not ensure patient safety and will hinder innovation, the group said.
The Senate should pattern its Medicare prescription drug bill after an earlier version introduced in the House that would let the federal government pursue lower drug costs through direct negotiation with drug companies, Sen. Debbie Stabenow (D-Mich.) said.
Two leading House members sent a letter to FDA Commissioner Andrew von Eschenbach asking him when he would have to alert agency employees about possible layoffs if the Prescription Drug User Fee Act (PDUFA) is not reauthorized.
As part of a Senate Finance Committee investigation, Sen. Chuck Grassley (R-Iowa) is requesting information from Eli Lilly regarding the marketing of its antipsychotic drug Zyprexa.